Esther;
There is a
GlaxoSmithKline Breast Cancer Study which I applied to that involves either Lapitinib as a single agent or in combination with another drug. Both are taken orally and you must present yourself to the hospitals every 4 weeks. Apparently this is open and not closing soon. I did not qualify as (thank goodness) as I have had no recurrence You must have active disease. I wanted to take this drug as I have been taken off herceptin so we have agreed that, although hopefully we will never speak again (lol) my file will remain in their books and if I do have a recurrence I will be put forward as a potential candidate. I live in the north so spoke to a woman at the Rochester NY address. Acurian forwarded my name to them after I found the link that Joe put on the site and completed the application. She responded very quickly and I would suggest that if think you would qualify (or not if you want to have the potential contact) complete the application.
Here is the information Joe posted:
We previously sent you an e-mail about three (3) breast cancer clinical research studies (clinical trials) being conducted in your area that may be of interest to you. The studies are evaluating the safety and effectiveness of an investigational oral drug, GW572016, for the treatment of advanced or metastatic, Stage III or IV, breast cancer in women. If you have already called about these clinical trials, there is no need to call again. However, if you have not called, we wanted to give you another opportunity to participate in these clinical trials.
Below are some of the criteria that you must meet to be eligible for this study: - Female, at least 18 years of age
- Diagnosed with Stage III or Stage IV breast cancer
- Able to swallow and retain oral medications
- Not currently pregnant or nursing.
Additional criteria will be evaluated to determine your eligibility.
All qualified study participants will receive the investigational drug at no cost. The length of study participation is dependent on how each woman and her tumor(s) respond to the study drug(s).
If these studies interest you and you wish to find out if you may be eligible to participate, we invite you to contact Acurian for pre-screening by
clicking here or calling toll free
1-800-563-6118.
About Acurian
Acurian is a company that specializes in education and awareness campaigns for clinical research studies. They are working with the sponsor of these studies to coordinate the pre-screening and referral of women to the research sites for further evaluation and consideration for participation in these breast cancer research studies.
Acurian's Privacy Statement:
Your responses to the pre-screening questions will be kept confidential and will only be shared with the research study doctor's staff to help them determine your final eligibility for this study. This de-identified data may also be shared with the study sponsor, and its representatives, should you be enrolled. Your information will be saved at Acurian only until the study is complete; then it will be destroyed. The decision to participate will be yours alone and you can change your mind at any time.
To see if you are eligible and get more information on the clinical trials, click here
http://www.cancerprofiler.nexcura.com/go/acurianbreast
or call toll-free 1-800-563-6118.
Hybrid Mode
